Cargando…

Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria

BACKGROUND: We aimed to evaluate the effect of immunosuppressant therapy for immunoglobulin A nephropathy (IgAN) patients with mild proteinuria (<1 g/d). METHODS: We recruited patients with biopsy-proven IgAN from 4 study centers. Patients were followed for more than 1 year or up to the study end...

Descripción completa

Detalles Bibliográficos
Autores principales: Pei, Gaiqin, Tan, Jiaxing, Tang, Yi, Tan, Li, Zhong, Zhengxia, Zhou, Ling, Chen, Changyun, Qin, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302656/
https://www.ncbi.nlm.nih.gov/pubmed/32541473
http://dx.doi.org/10.1097/MD.0000000000020513
_version_ 1783547894605807616
author Pei, Gaiqin
Tan, Jiaxing
Tang, Yi
Tan, Li
Zhong, Zhengxia
Zhou, Ling
Chen, Changyun
Qin, Wei
author_facet Pei, Gaiqin
Tan, Jiaxing
Tang, Yi
Tan, Li
Zhong, Zhengxia
Zhou, Ling
Chen, Changyun
Qin, Wei
author_sort Pei, Gaiqin
collection PubMed
description BACKGROUND: We aimed to evaluate the effect of immunosuppressant therapy for immunoglobulin A nephropathy (IgAN) patients with mild proteinuria (<1 g/d). METHODS: We recruited patients with biopsy-proven IgAN from 4 study centers. Patients were followed for more than 1 year or up to the study end point. Clinical indexes, renal pathological data, and treatment information were collected during the follow-up period. IgAN patients with mild proteinuria (<1 g/d at biopsy) were included. Patients were divided into a supportive care group (SC) and an immunosuppressant group (IT). Patients in the SC group received the optimal dose of renin angiotensin system inhibitors (RASi). Patients in the IT group received corticosteroids or immunosuppressant therapy plus RASi. Responses to therapy included complete remission (CR), partial remission (PR), no response (NR), and end stage renal disease (ESRD). A 50% decline in estimated glomerular filtration rate (eGFR) and/or ESRD was the primary end point of this study. RESULTS: 295 patients (36.3% male and 63.7% female) were included in this study and were followed for 49.46 ± 24.35 months. We found a significant difference in estimated glomerular filtration rate, urine protein, mesangial hypercellularity, segmental glomerulosclerosis, cellular or fibrocellular crescents, and glomerulosclerosis between the 2 treatment groups at baseline. At the final follow-up, 224 patients (75.9%) achieved CR, 7 patients (2.4%) achieved PR, 55 patients (18.6%) had NR, and 9 patients (3.1%) reached ESRD. However, no significant differences were observed between the SC and IT groups with respect to CR (76.4% vs 73.5%, P = .659), PR (2.0% vs 4.1%, P = .329), NR (18.3% vs 20.4%, P = .728), and ESRD (3.3% vs 2.0%, P = 1.000). Kidney survival rates were also comparable between the SC and IT groups (93.7% vs 94.1%, P = .808). We observed similar results after subgroup analysis according to chronic kidney disease stages or pathological manifestations. A multivariate model showed that segmental sclerosis (HR 9.55, 95% CI 1.04–88.16, P = .047) and glomerulosclerosis (HR 21.09, 95% CI 1.39–320.53, P = .028) were independent predictors of poor renal survival. CONCLUSIONS: Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.
format Online
Article
Text
id pubmed-7302656
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-73026562020-06-29 Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria Pei, Gaiqin Tan, Jiaxing Tang, Yi Tan, Li Zhong, Zhengxia Zhou, Ling Chen, Changyun Qin, Wei Medicine (Baltimore) 5200 BACKGROUND: We aimed to evaluate the effect of immunosuppressant therapy for immunoglobulin A nephropathy (IgAN) patients with mild proteinuria (<1 g/d). METHODS: We recruited patients with biopsy-proven IgAN from 4 study centers. Patients were followed for more than 1 year or up to the study end point. Clinical indexes, renal pathological data, and treatment information were collected during the follow-up period. IgAN patients with mild proteinuria (<1 g/d at biopsy) were included. Patients were divided into a supportive care group (SC) and an immunosuppressant group (IT). Patients in the SC group received the optimal dose of renin angiotensin system inhibitors (RASi). Patients in the IT group received corticosteroids or immunosuppressant therapy plus RASi. Responses to therapy included complete remission (CR), partial remission (PR), no response (NR), and end stage renal disease (ESRD). A 50% decline in estimated glomerular filtration rate (eGFR) and/or ESRD was the primary end point of this study. RESULTS: 295 patients (36.3% male and 63.7% female) were included in this study and were followed for 49.46 ± 24.35 months. We found a significant difference in estimated glomerular filtration rate, urine protein, mesangial hypercellularity, segmental glomerulosclerosis, cellular or fibrocellular crescents, and glomerulosclerosis between the 2 treatment groups at baseline. At the final follow-up, 224 patients (75.9%) achieved CR, 7 patients (2.4%) achieved PR, 55 patients (18.6%) had NR, and 9 patients (3.1%) reached ESRD. However, no significant differences were observed between the SC and IT groups with respect to CR (76.4% vs 73.5%, P = .659), PR (2.0% vs 4.1%, P = .329), NR (18.3% vs 20.4%, P = .728), and ESRD (3.3% vs 2.0%, P = 1.000). Kidney survival rates were also comparable between the SC and IT groups (93.7% vs 94.1%, P = .808). We observed similar results after subgroup analysis according to chronic kidney disease stages or pathological manifestations. A multivariate model showed that segmental sclerosis (HR 9.55, 95% CI 1.04–88.16, P = .047) and glomerulosclerosis (HR 21.09, 95% CI 1.39–320.53, P = .028) were independent predictors of poor renal survival. CONCLUSIONS: Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria. Wolters Kluwer Health 2020-06-12 /pmc/articles/PMC7302656/ /pubmed/32541473 http://dx.doi.org/10.1097/MD.0000000000020513 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 5200
Pei, Gaiqin
Tan, Jiaxing
Tang, Yi
Tan, Li
Zhong, Zhengxia
Zhou, Ling
Chen, Changyun
Qin, Wei
Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria
title Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria
title_full Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria
title_fullStr Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria
title_full_unstemmed Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria
title_short Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria
title_sort corticosteroids or immunosuppressants were not superior to supportive care in iga nephropathy patients with mild proteinuria
topic 5200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302656/
https://www.ncbi.nlm.nih.gov/pubmed/32541473
http://dx.doi.org/10.1097/MD.0000000000020513
work_keys_str_mv AT peigaiqin corticosteroidsorimmunosuppressantswerenotsuperiortosupportivecareiniganephropathypatientswithmildproteinuria
AT tanjiaxing corticosteroidsorimmunosuppressantswerenotsuperiortosupportivecareiniganephropathypatientswithmildproteinuria
AT tangyi corticosteroidsorimmunosuppressantswerenotsuperiortosupportivecareiniganephropathypatientswithmildproteinuria
AT tanli corticosteroidsorimmunosuppressantswerenotsuperiortosupportivecareiniganephropathypatientswithmildproteinuria
AT zhongzhengxia corticosteroidsorimmunosuppressantswerenotsuperiortosupportivecareiniganephropathypatientswithmildproteinuria
AT zhouling corticosteroidsorimmunosuppressantswerenotsuperiortosupportivecareiniganephropathypatientswithmildproteinuria
AT chenchangyun corticosteroidsorimmunosuppressantswerenotsuperiortosupportivecareiniganephropathypatientswithmildproteinuria
AT qinwei corticosteroidsorimmunosuppressantswerenotsuperiortosupportivecareiniganephropathypatientswithmildproteinuria